We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+1.03%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$746M
AUM Growth
+$13.3M
Cap. Flow
-$7.63M
Cap. Flow %
-1.02%
Top 10 Hldgs %
47.22%
Holding
107
New
21
Increased
25
Reduced
20
Closed
22

Top Buys

Rank Stock Value
1
APGE
Apogee Therapeutics
APGE
+$13.6M
2
MRUS
Merus
MRUS
+$10.9M
3
ARVN icon
Arvinas
ARVN
+$9.84M
4
SYRE icon
Spyre Therapeutics
SYRE
+$9.56M
5
PRQR icon
ProQR Therapeutics
PRQR
+$8.97M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$13.4M
2
ATXS
Astria Therapeutics
ATXS
+$7.98M
3
VRDN icon
Viridian Therapeutics
VRDN
+$7.94M
4
ONC
BeOne Medicines Ltd
ONC
+$7.86M
5
TERN
Terns Pharmaceuticals
TERN
+$5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.04%
2 Miscellaneous 21.48%
3 Financials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OACCU
51
Oaktree Acquisition Corp III Life Sciences Unit
OACCU
$2.54M 0.34%
+250,000
New +$2.52M
IMVT icon
52
Immunovant
IMVT
$8.11B
$2.48M 0.33%
100,000
-125,000
-56% -$3.55M
JBIO
53
Jade Biosciences
JBIO
$1.27B
$2.12M 0.28%
22,857
+5,714
+33% +$492K
PCVX icon
54
Vaxcyte
PCVX
$9.1B
$2.05M 0.27%
25,000
-25,000
-50% -$2.48M
NKTX icon
55
Nkarta
NKTX
$209M
$1.99M 0.27%
800,000
+150,000
+23% +$463K
NXTC icon
56
NextCure
NXTC
$35.8M
$1.78M 0.24%
191,883
– –
AVR
57
Anteris Technologies
AVR
$881M
$1.67M 0.22%
+300,000
New +$1.68M
KYMR icon
58
Kymera Therapeutics
KYMR
$9.76B
$1.61M 0.22%
+40,000
New +$1.81M
APLS
59
DELISTED
Apellis Pharmaceuticals
APLS
$1.6M 0.21%
+50,000
New +$1.5M
RAPT
60
DELISTED
RAPT Therapeutics
RAPT
$1.58M 0.21%
+125,000
New +$1.59M
NARI
61
DELISTED
Inari Medical, Inc. Common Stock
NARI
$1.28M 0.17%
25,000
-35,000
-58% -$1.72M
SVRA icon
62
Savara
SVRA
$1.1B
$1.26M 0.17%
410,586
-289,414
-41% -$1.01M
OKUR
63
OnKure Therapeutics
OKUR
$145M
$1.24M 0.17%
+144,159
New +$2.18M
BDTX icon
64
Black Diamond Therapeutics
BDTX
$122M
$1.2M 0.16%
+559,163
New +$1.6M
CNTX icon
65
Context Therapeutics
CNTX
$33.2M
$1.07M 0.14%
1,015,340
-305,813
-23% -$529K
KZR
66
DELISTED
Kezar Life Sciences
KZR
$956K 0.13%
142,316
-108,862
-43% -$811K
CLYM
67
Climb Bio
CLYM
$891M
$900K 0.12%
500,000
-1,000,000
-67% -$3.62M
RADX
68
Radiopharm Theranostics
RADX
$30.1M
$684K 0.09%
+156,171
New +$1.03M
IBRX icon
69
PUT
ImmunityBio
IBRX
$8.56B
$640K 0.09%
+250,000
New +$1.04M
BMEA icon
70
PUT
Biomea Fusion
BMEA
$147M
$582K 0.08%
+150,000
New +$1.2M
ZURA icon
71
Zura Bio
ZURA
$597M
$558K 0.07%
223,335
– –
SYRS
72
PUT
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$354K 0.05%
1,541,200
+307,000
+25% +$368K
CLDX icon
73
Celldex Therapeutics
CLDX
$3.12B
$252K 0.03%
9,992
-115,008
-92% -$3.12M
ADGM
74
Adagio Medical Holdings
ADGM
$12.5M
$224K 0.03%
213,235
– –
RPTX
75
DELISTED
Repare Therapeutics
RPTX
$131K 0.02%
100,000
-73,351
-42% -$218K
1 2
3
4 5

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Affinity Asset Advisors held 107 positions worth $746M, up 1.8% from $733M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Affinity Asset Advisors's Q4 2024 filing shows 21 new, 25 increased, 20 reduced and 22 closed positions. Its largest new stake was ProQR Therapeutics: 2,825,000 shares worth $7.49M. The largest sale was Kura Oncology, an estimated $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 82% a quarter earlier, followed by Miscellaneous and Financials.

  • Affinity Asset Advisors's largest Q4 2024 buy was ProQR Therapeutics: 2,825,000 shares worth $7.49M.
  • Affinity Asset Advisors added most to Apogee Therapeutics in Q4 2024, an estimated $13.6M increase.
  • Affinity Asset Advisors's biggest Q4 2024 reduction was Viridian Therapeutics, cutting an estimated $7.94M.
  • Affinity Asset Advisors fully exited Kura Oncology in Q4 2024, selling an estimated $13.4M.
  • Affinity Asset Advisors's ten largest holdings make up 47% of its $746M portfolio in Q4 2024.
  • Affinity Asset Advisors opened 21 new positions and closed 22 in Q4 2024.
  • Affinity Asset Advisors's portfolio value rose 1.8% quarter-over-quarter to $746M.

Based on Affinity Asset Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.